ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Adenocarcinoma
Recurrence
Castration-Resistant Prostatic Cancer

Prostate Cancer trials near Montréal, QC, CAN:

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in t ...

Active, not recruiting
Prostate Cancer
Drug: Docetaxel
Drug: 177Lu-PSMA-617

Phase 2

Canadian Cancer Trials Group

Montreal, Quebec, Canada and 9 other locations

androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate...

Active, not recruiting
Prostate Cancer
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog

Phase 3

University of Sydney

Montréal, Quebec, Canada and 92 other locations

ACCEL is a multicenter, open label phase I/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-pos ...

Enrolling
Biochemically Recurrent Prostate Carcinoma
Metastatic Castration-resistant Prostate Cancer
Drug: [Ac-225]-PSMA-62 (BCR)
Drug: [Ac-225]-PSMA-62 (mCRPC)

Phase 1

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Montréal, Quebec, Canada

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-560219...

Active, not recruiting
Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms
Drug: Prednisone
Drug: JNJ-56021927

Phase 1

Aragon Pharmaceuticals

Montreal, Quebec, Canada and 6 other locations

Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...

Active, not recruiting
Prostate Cancer Metastatic
Drug: ARV-110 in Combination with Abiraterone

Phase 1

Arvinas
Arvinas

Montreal, Quebec, Canada and 17 other locations

and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: abiraterone acetate
Drug: olaparib

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 131 other locations

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side eff...

Active, not recruiting
Prostate Cancer
Drug: Palbociclib

Phase 2

Canadian Cancer Trials Group

Montreal, Quebec, Canada and 6 other locations

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk t...

Enrolling
Prostate Cancer
Drug: Eligard

Phase 2

McGill University
McGill University

Montréal, Quebec, Canada and 1 other location

approach.Participants with high-risk prostate cancer planned for curative-intent standard-of-care radiotherapy or surgery, or with...

Active, not recruiting
Prostate Cancer
Other: Control Arm
Diagnostic Test: PSMA PET/CT guided intensification of therapy

Phase 3

Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, Canada and 18 other locations

It is a phase I study of radical hypofractionation delivering one single fraction of SBRT in patients with low- and favorable intermediate-risk prostate...

Enrolling
Prostate Cancer
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Fabio Cury

Montréal, Quebec, Canada

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems